hackint0sh/New-Dataset huggingface dataset:
Participants will be will be divided into two groups, with one group having their wisdom teeth removed 6 months before their jaw moving surgery and the other group having their wisdom teeth removed in connection with their jaw moving surgery. conditions: Impacted Third Molar Tooth conditions: Osteotomy conditions: Orthognathic Surgery conditions: Mandibular Fractures studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial with a test group and a control group. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 150 type: ESTIMATED name: Interoperative wisdom tooth removal in conjunction with BSSO measure: Fracture pattern following BSSO with or without impacted third molars measure: Condylar segment position following BSSO with or without impacted third molars measure: Oral Health Impact Profile-14 (OHIP-14) measure: The Modified Dental Anxiety Scale (MDAS) measure: Short Form-36 (SF-36) measure: PROMs measure: Length of the surgical procedure measure: Intraoperative bleeding measure: Frequency of intra- and postoperative complications sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aalborg universitets hospital city: Aalborg zip: 9000 country: Denmark lat: 57.048 lon: 9.9187 hasResults: False
nctId: NCT06338969 id: PostBariKetosis briefTitle: The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis overallStatus: RECRUITING date: 2024-03-25 date: 2025-04-01 date: 2025-08-01 date: 2024-04-01 date: 2024-04-03 name: The Society of Bariatric and Metabolic Surgeons of Kazakhstan class: OTHER briefSummary: Background:
The study aimed to compare the incidence of ketoacidosis and liver failure in patients with NASH with different intakes of carbohydrates in the early postoperative period after gastric bypass. In addition, the investigators want to find out how carbohydrate restriction will affect weight loss for up to 1 year. conditions: Obesity, Morbid conditions: NASH conditions: Ketosis conditions: Keto Acidosis conditions: Carbohydrate Metabolism Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: Carbohydrate Restriction after a Gastric Bypass measure: Cases of ketosis and incidence of ketoacidosis measure: Cases of liver failure measure: Change in body mass index (Δ BMI) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Oral Ospanov status: RECRUITING city: Astana state: Aqmola zip: 010000 country: Kazakhstan name: Oral Ospanov, PhD role: CONTACT phone: 7015287734 phoneExt: +7 email: bariatric.kz@gmail.com lat: 51.1801 lon: 71.44598 hasResults: False
nctId: NCT06338956 id: Lipid-PCI briefTitle: Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI acronym: Lipid-PCI overallStatus: RECRUITING date: 2024-01-01 date: 2024-12-31 date: 2025-12-31 date: 2024-04-01 date: 2024-04-01 name: Samsung Medical Center class: OTHER briefSummary: For the management of low-density lipoprotein-cholesterol (LDL-C), some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in LDL-C levels. High-intensity or maximally tolerated intensity can be maintained without a target goal. However, the European guideline recommends less than 55 mg/dL of LDL-C after PCI. conditions: Coronary Artery Disease conditions: Hyperlipidemias studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 94189 type: ESTIMATED name: LDL reduction therapy measure: MACCE measure: Cardiovascular death measure: Spontaneous myocardial infarction measure: Repeat revascularization measure: Ischemic stroke sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Samsung Medical Center status: RECRUITING city: Seoul country: Korea, Republic of name: Ki Hong Choi, MD role: CONTACT phone: 82-2-3410-3419 email: cardiokh@gmail.com lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06338943 id: 02-02/24 briefTitle: Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction acronym: MAPO-HF overallStatus: RECRUITING date: 2024-03-18 date: 2025-01 date: 2025-01 date: 2024-04-01 date: 2024-04-01 name: National Medical Research Center for Therapy and Preventive Medicine class: OTHER_GOV briefSummary: Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease. Nowadays, the relationship of adverse pregnancy factors with the development of long-term cardiac pathology, in particular, HFpEF, has not been completely established. One of the most significant issue is studying the younger phenotype of women.
Primary endpoint: The prevalence of HFpEF in patients with the history of APOs. conditions: Heart Failure Preserved Ejection Fraction conditions: Pregnancy Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: Echocardiography name: Questionnaire measure: HFpEF incidence measure: APOs incidence sex: FEMALE minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT facility: National Medical Research Center for Therapy and Preventive Medicine status: RECRUITING city: Moscow country: Russian Federation name: Olga Dzhioeva, MD, PhD role: CONTACT phone: +79166141821 email: odzhioeva@gnicpm.ru name: Max Shperling, MD role: PRINCIPAL_INVESTIGATOR name: Alexandr Mols role: SUB_INVESTIGATOR lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06338930 id: ROADMAP briefTitle: Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no or Maintenance Therapy acronym: ROADMAP overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-03-02 date: 2027-03-30 date: 2024-04-01 date: 2024-04-01 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: Routine follow-up of patients with inflammatory bowel disease (IBD) under stable doses of maintenance therapy or no IBD-related therapy at all, consists of intensive monitoring with prescheduled outpatient visits every six or twelve months. However, many of these patients do not require additional interventions from the IBD specialist during these visits. In addition, patients in long-term remission, often request a less frequent follow-up in the hospital and in consequence a less frequent absence from school or work. In conclusion, these routinely follow-up visits might put unnecessary burden on both healthcare providers and IBD patients, as well as on healthcare resources.
Until now, no clear standard was set for how to organize a remote monitoring programme that is feasible and safe in a large patient population. Despite the possible added value of remote monitoring for IBD patients on stable or no therapy and who are in remission, they are seldomly the targeted population in clinical trials analysing the effects of remote monitoring in IBD. Secondly, a significant reduction in outpatient clinic visits, is often not actively included in the programme, but more an outcome result. Finally, to compose a safe remote monitoring programme, subjective and objective parameters of disease activity should be collected.
With the ROADMAP study, the main objective is to evaluate the safety and feasibility of remote monitoring in IBD patients that are stable on their current therapy or receive no IBD-related therapy. Secondly, a health economic evaluation will be conducted. Patients will be randomised to either the remote monitoring group or control group. The remote monitoring group will visit the outpatient clinic after two years. During this two-year period, patients will be monitored remotely via three-monthly questionnaires (PRO-2, IBD disk, WPAI, EQ-5D-5L) and faecal calprotectin measures. An IBD nurse will evaluate all incoming data and act in case of red flags. conditions: Crohn Disease conditions: Colitis, Ulcerative conditions: Inflammatory Bowel Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 456 type: ESTIMATED name: Remote monitoring measure: Patient safety measured as the number of patients not requiring unplanned IBD related hospital visits (outpatient clinic, emergency department, hospitalization, or surgery) or rescue therapy with steroids within two years. measure: Costs and cost savings for hospital, RIZIV, employer, patient, … in the intervention group versus the control group. measure: Time saving for patients in the intervention group versus the control group will be measured using a "timing questionnaire". measure: Number of telephone/email contacts with the IBD team within one year and within two years. measure: Number of contacts with the general practitioner for IBD related reasons within one year and within two years. measure: Absence at work or school within one year and within two years in the intervention group versus the control group will be measured using the WPAI IBD questionnaire. measure: Quality of life in the intervention group versus the control group will be measured using the European Quality of Live Five Dimension Five Level Scale. measure: Number of patients refusing to participate in this trial and the reason why. measure: Reasons to stop remote monitoring. measure: Patient's compliance, measured via missing data in the intervention versus the control group measure: Satisfaction with the program in the intervention group. measure: System usability in the intervention group. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06338917 id: File 2022 DI 61 briefTitle: Mental Health and Vigorous-intensity Physical Activity acronym: +MoveMENT overallStatus: ENROLLING_BY_INVITATION date: 2023-09-10 date: 2026-01-31 date: 2026-01-31 date: 2024-04-01 date: 2024-04-01 name: University of Vic - Central University of Catalonia class: OTHER name: IRIS-CC name: AGAUR briefSummary: People with severe mental illness have unhealthy lifestyles and habits, such as sedentary behavior and physical inactivity. Which are associated with a higher prevalence of premature mortality and chronic comorbidities.
The aim of this study is to evaluate the efficacy of a physical activity program, which pretends to increase the number of vigorous-intensity physical activity bouts in their daily life, as a habit, combining High Intensity Interval Training (HIIT) and Vigorous Intensity Life-Style Physical Activity (VILPA). Secondary aims are to evaluate the efficacy of the program on fitness, physical activity and sedentary behavior level and patron; depressive, mania and psychotic symptomatology, functionality and cognitive functioning; quality of life and mood. conditions: Mental Health Issue studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE maskingDescription: Participants in both groups are not aware of the existence of the other group. The health provider in the control group is aware of the existence of the intervention group but does not know which intervention is being carried out. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: Vigorous-intensity physical activity program measure: Psychotic symptomatology measure: Depression symptomatology measure: Depression severity measure: Mania symptomatology measure: Mania severity measure: Disability measure: Quality of life measure: Cognitive functioning measure: Mood measure: Subjective physical activity patron measure: Subjective sedentary behaviour patron measure: Perception of physical fitness measure: Objective physical activity patron measure: Objective sedentary behavior patron measure: Cardiorespiratory endurance measure: Velocity measure: Agility measure: Lower limb strength measure: Subjective perception of joy measure: Subjective perception of calm measure: Subjective perception of energy measure: Subjective perception of time spent measure: Subjective perception of the received information measure: Subjective perception of respect received sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Vic city: Vic state: Barcelona zip: 08500 country: Spain lat: 41.93012 lon: 2.25486 hasResults: False
nctId: NCT06338891 id: ACPM34 briefTitle: Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks overallStatus: RECRUITING date: 2024-05-01 date: 2024-08-30 date: 2025-05-01 date: 2024-04-01 date: 2024-04-01 name: University of Palermo class: OTHER briefSummary: Familial Mediterranean Fever (FMF) is a chronic hereditary autoinflammatory disease caused by mutations in the MEditerranean FeVer (MEFV) gene which codes for pyrin. Dysfunction of this protein determines an inappropriate response to inflammatory stimuli. The clinical course of the disease is characterized by recurrent episodes of fever and inflammation of the serous membranes, which manifest with chest, abdominal and joint pain. Several studies suggest a possible association between acute FMF attacks and dietary triggers, including wheat. However, it is still unclear to what extent wheat is responsible for the reactivation of FMF and if, between one acute attack and another, patients with FMF experience other symptoms, both gastrointestinal and extraintestinal, characteristic of gluten/wheat sensitivity not linked to celiac disease or immunoglobulin E (IgE)-mediated wheat allergy (i.e. Non-Celiac Wheat Gluten/Sensitivity, NCGS/NCWS).
nctId: NCT06338878 id: 2023PI087 briefTitle: PAtient Treatment Analysis: Hospital and Wide-ranging Out-of-hospital Care Assessment Yields Insights Into Heart Failure Outcomes acronym: PATHWAY-HF overallStatus: RECRUITING date: 2024-03-01 date: 2027-01 date: 2029-01 date: 2024-04-01 date: 2024-04-01 name: Pr. Nicolas GIRERD class: OTHER briefSummary: This is a monocentric cohort study conducted in the cardiology department of Nancy hospital. The main purpose of the study is to document the global management strategy of patients hospitalized for heart failure and evaluate the association between patient's care and post-hospitalization outcome. conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: All-cause post-hospitalization mortality measure: Rehospitalization for heart failure measure: Percentage of maximum dose of each cardiotropic treatment indicated in heart failure according to ESC recommendations measure: Influenza and pneumococcal vaccination status measure: Evolution of renal function measure: All-cause Rehospitalization measure: All-cause mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHRU de Nancy status: RECRUITING city: Nancy country: France name: Laura FILIPPETTI role: CONTACT email: l.filippetti@chru-nancy.fr lat: 48.68439 lon: 6.18496 hasResults: False
nctId: NCT06338865 id: Study00003146 briefTitle: Short Title: Standard vs. Lower Pressure Pneumoperitoneum overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2027-04 date: 2024-04-01 date: 2024-04-01 name: Cedars-Sinai Medical Center class: OTHER briefSummary: This study aims to investigate the effect of varying insufflation pressures on post-operative pain and adequacy of surgical field visualization among patients undergoing laparoscopic surgery with a minimally invasive gynecologic surgeon. conditions: Laparoscopic Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Patients and post-anesthesia care unit nurses will be masked. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 294 type: ESTIMATED name: Carbon dioxide name: Bupivacaine name: Oxycodone measure: Maximum documented pain score in post-anesthesia care unit (PACU) (numerical rating scale, 0-10) measure: First reported pain score in PACU (numerical rating scale, 0-10) measure: Last reported pain score in PACU prior to discharge (numerical rating scale, 0-10) measure: Inpatient morphine milligram equivalents measure: Total number of 5mg oxycodone pills taken in the 2 weeks following discharge measure: Need for insufflation pressure increase intra-operatively due to inadequate visualization measure: Operative time measure: Estimated blood loss measure: Intraoperative complications measure: Conversion to laparotomy measure: Postoperative length of stay measure: Surgeon-reported adequacy of assigned insufflation pressure measure: Need for adjustment of insufflation pressure sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06338852 id: 4347 briefTitle: Awareness of Gynaecologists About Role of Physical Therapy in Genital Prolapse overallStatus: COMPLETED date: 2023-03-03 date: 2023-06-03 date: 2023-07-03 date: 2024-04-01 date: 2024-04-01 name: Cairo University class: OTHER briefSummary: The aim of this study will be to detect if there is awareness of gynecologists about the role of physical therapy in genital prolapse.
Physical therapy treatments for the pelvic floor may include bladder training, pelvic floor muscles training with or without biofeedback, vaginal cones, electro stimulation or other adjuncts to training. conditions: Genital Prolapse studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 370 type: ACTUAL name: Socio demographic and evaluation questionnaires measure: Socio demographic and evaluation questionnaires sex: ALL minimumAge: 29 Years maximumAge: 44 Years stdAges: ADULT facility: Faculty of physical therapy cairo university city: Cairo zip: 37617692 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06338839 id: D8450R00006 briefTitle: Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia acronym: TETRAMER overallStatus: RECRUITING date: 2023-12-28 date: 2024-11-30 date: 2024-11-30 date: 2024-04-01 date: 2024-04-01 name: AstraZeneca class: INDUSTRY briefSummary: A multicenter observational retrospective-prospective study of prevalence and clinical characteristics of transthyretin amyloidosis (ATTR) cardiomyopathy (CM) in Russian patients with heart failure with preserved ejection fraction (HFpEF) in real clinical practice.
The retrospective phase will entail secondary data collection from electronic or paper medical records of patients who are participating/participated in the PRIORITY-CHF study and have HFpEF. Those patients who have a high suspicion of having ATTR-CM and provided informed consent will be invited to participate in the prospective phase. The prospective phase will consist of three visits, during which a routine comprehensive cardiologic evaluation in order to confirm or exclude ATTR-CM diagnosis will be performed. In patients with confirmed ATTR-CM the material for genetic testing will be collected in order to specify the type of ATTR-amyloidosis conditions: Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 6000 type: ESTIMATED measure: Prevalence of ATTR-CM in patients with HFpEF in routine clinical practice in the Russian Federation measure: demographic and clinical characteristics, and test results sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site status: RECRUITING city: Akhtubinsk country: Russian Federation lat: 48.27955 lon: 46.17217 facility: Research Site status: RECRUITING city: Astrakhan country: Russian Federation lat: 46.34968 lon: 48.04076 facility: Research Site status: RECRUITING city: Beslan country: Russian Federation lat: 43.19217 lon: 44.54313 facility: Research Site status: RECRUITING city: Izhevsk country: Russian Federation lat: 56.84976 lon: 53.20448 facility: Research Site status: RECRUITING city: Kaluga country: Russian Federation lat: 54.5293 lon: 36.27542 facility: Research Site status: RECRUITING city: Krasnodar country: Russian Federation lat: 45.04484 lon: 38.97603 facility: Research Site status: RECRUITING city: Rostov-on-Don country: Russian Federation lat: 47.23135 lon: 39.72328 facility: Research Site status: RECRUITING city: Smolensk country: Russian Federation lat: 54.7818 lon: 32.0401 facility: Research Site status: RECRUITING city: Vladimir country: Russian Federation lat: 56.13655 lon: 40.39658 facility: Research Site status: RECRUITING city: Vladivostok country: Russian Federation lat: 43.10562 lon: 131.87353 facility: Research Site status: RECRUITING city: Volgograd country: Russian Federation lat: 48.71939 lon: 44.50183 facility: Research Site status: RECRUITING city: Yaroslavl country: Russian Federation lat: 57.62987 lon: 39.87368 hasResults: False
nctId: NCT06338826 id: ANRS0250s-BI-LIGHT briefTitle: Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses acronym: BI-LIGHT overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-02-28 date: 2027-02-28 date: 2024-04-01 date: 2024-04-01 name: ANRS, Emerging Infectious Diseases class: OTHER_GOV briefSummary: The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy conditions: HIV Infections conditions: HBV Coinfection studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Interventional, sequential, Phase IIA equivalent, multicenter, open-label, randomized, non-comparative study evaluating, for 96 weeks, the safety in terms of HBV virological control of 2 antiviral therapy relief strategies, in HIV-1 and HBV co-infected patients with prolonged virological success (undetectable HIV-1 and HBV viral loads for ≥ 2 years) and on unmodified antiviral therapy for ≥ 1 year.
* Arm 3 (B7): Switch from prior triple antiviral therapy (containing TDF or TAF) to continuous dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR). The choice of dual therapy is left to the discretion of the investigator. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 140 type: ESTIMATED name: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI name: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) measure: The proportion of participants with HBV virological failure at 96 weeks. measure: • HBV virological success rate at 48 weeks measure: • HIV virological success rate at 48 and 96 weeks measure: • Time to virological failure (rebound HBV and/or HIV viral load) measure: • The rate of participants with at least one HBV viral load blip until W48 and until W96 measure: • Selection of HBV resistance mutations at the time of virological failure measure: • Incidence of grade 3 or higher adverse events of grade 3 or higher, incidence of adverse events and incidence of strategy discontinuation of the strategy at W48 and W96 measure: • Evolution of CD4 from W0 to W48 and W96 measure: • Evolution of total cholesterol from W0 to W48 and W96 measure: • Evaluation of the adherence by self-reported questionnaire measure: • Evaluation of quality of life using the Pro-Qol self-questionnaire measure: Evolution of CD8 T lymphocytes from W0 to W48 and W96 measure: Evolution of the CD4/CD8 ratio from W0 to W48 and W96 measure: Evolution of LDL-c from W0 to W48 and W96 measure: Evolution of HDL-c from W0 to W48 and W96 measure: Evolution of triglycerides from W0 to W48 and W96 measure: Evolution of fasting blood sugar from W0 to W48 and W96 measure: HBV virological success rate at 96 weeks between arms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False